

Attorney Docket No. UM-06609

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James R. Baker, Jr.

Serial No.:

09/940,243

Group No.: 1635

Filed:

08/27/2001

Examiner:

Ashen, J.

Entitled:

Multifunctional Nanodevice Platform

# INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 4, 2005.

Mary Ellen Waite

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated:

August 4, 2005

David A. Casimir

Registration No. 42,395

08/09/2005 CNGUYEN2 00000024 09940243

01 FC:1806

180.00 OP

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 305 San Francisco, California 94105 608/218-6900

Group No.: 1635



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James R. Baker, Jr.

Serial No.: 09/940,243

Filed: 08/27/2001 Examiner: Ashen, J.

Entitled: Multifunctional Nanodevice Platform

# INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, MA 22313-1450.

By:

Dated: August 4, 2005

Mary Ellen Waite

#### Dear Sir or Madam:

The citations listed below, copies to follow, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- U.S. Patent 4,507,466;
- U.S. Patent 4,558,120;
- U.S. Patent 4,568,737;
- U.S. Patent 4,587,329;
- U.S. Patent 4,631,337;

- U.S. Patent 4,694,064;
- U.S. Patent 4,713,975;
- U.S. Patent 4,737,550;
- U.S. Patent 4,857,599;
- U.S. Patent 4,871,779;
- U.S. Patent 5,338,532;
- U.S. Patent 5,387,617;
- U.S. Patent 5,393,797;
- U.S. Patent 5,393,795;
- U.S. Patent 5,527,524;
- U.S. Patent 5,560,929;
- U.S. Patent 5,773,527;
- U.S. Patent 5,631,329;
- U.S. Patent 5,902,863;
- U.S. Patent 5,795,582;
- U.S. Patent 5,898,005;
- U.S. Patent 5,861,319;
- U.S. Patent 5,661,025;
- U.S. Patent 4,946,778;
- U.S. Patent 5,935,114;
- U.S. Patent 5,908,413;
- U.S. Patent 5,792,105;
- U.S. Patent 5,693,014;
- U.S. Patent 5,674,192;
- U.S. Patent 5,876,445;
- U.S. Patent 5,913,894;
- U.S. Patent 5,868,719;
- U.S. Patent 5,851,228;
- U.S. Patent 5,843,089;
- U.S. Patent 5,800,519;
- U.S. Patent 5,800,508;
- U.S. Patent 5,800,391;

- U.S. Patent 5,354,308;
- U.S. Patent 5,755,722;
- U.S. Patent 5,733,303;
- U.S. Patent 5,866,561;
- U.S. Patent 5,857,998;
- U.S. Patent 5,843,003;
- U.S. Patent 5,933,145;
- U.S. Patent 5,892,020;
- U.S. Patent 5,892,019;
- U.S. Patent 5,512,443;
- U.S. Patent 5,693,763;
- U.S. Patent 5,545,530;
- U.S. Patent 5,808,005;
- U.S. Patent 5,110,911;
- U.S. Patent 4,708,930;
- U.S. Patent 4,743,543;
- U.S. Patent 4,921,789;
- U.S. Patent 4,921,790;
- U.S. Patent 5,855,866;
- U.S. Patent 4,963,484;
- U.S. Patent 5,053,489;
- U.S. Patent 4,939,240;
- U.S. Patent 4,918,164;
- U.S. Patent 4,914,021;
- U.S. Patent 4,892,935;
- U.S. Patent 5,475,096;
- U.S. Patent 5,270,163;
- U.S. Patent 5,475,096;
- International Patent Publication WO 97/38134;
- International Patent Publication WO 98/33941;
- International Patent Publication WO 99/07724;
- PCT/US90/02545;

- Friedmann, Cancer 70:1810 [1992];
- Kerr et al., Cancer 73:2013 [1994];
- Cohen and Tohoku, Exp. Med., 168:351 [1992];
- Fujiwara et al., J. Natl. Cancer Inst., 86:458 [1994];
- Tomalia, Advanced Materials 6:529 [1994];
- Tomalia, Angew, Chem. Int. Ed. Engl., 29:138 [1990];
- Tomalia et al., Chem. Int. Ed. Engl., 29:5305 [1990];
- Yin et al., J. Am. Chem. Soc., 120:2678 [1998];
- Roberts et al., J. Biomed. Mat. Res., 30:53 [1996];
- Bourne et al., J. Magn. Reson. Imag., 6:305 [1996];
- Singh *et al.*, Clin. Chem., 40:1845 [1994];
- Wu et al., Bioorg. Med. Chem. Lett., 4:449 [1994];
- Wiener et al., Magn. Reson. Med. 31:1 [1994];
- Barth et al., Bioconjugate Chem. 5:58 [1994];
- Duncan and Malik, Control Rel. Bioact. Mater. 23:105 [1996];
- Baker et al., Anal. Chem. 69:990 [1997];
- Urdea and Hom, Science 261:534 [1993];
- Lanni et al., Proc. Natl. Acad. Sci., 94:9679 [1997];
- Tortora et al., Cancer Research 57:5107 [1997];
- Zaffaroni et al., Brit. J. Cancer 77:1378 [1998];
- Yu et al., Molecular Cell. 2:581 [1998];
- Gibb, Gynecologic Oncology 65:13 [1997];
- Akutsu *et al.*, Eur. J. Cancer 31A:2341 [1995];
- Goodman and Gilman's "Pharmaceutical Basis of Therapeutics" ninth edition, Eds. Hardman *et al.*, 1996. This reference is a book and is not being supplied at this time;
- Pasani et al., Inorg. Chim. Acta 80:99 [1983];
- Ottl *et al.*, Bioconjugate Chem., 9:143 [1998]:
- Abel et al., Eur. J. Cancer 9:4 [1973];
- Pillai, V.N.R. Synthesis: 1-26 [1980];
- Esfand et al., Pharm. Sci., 2:157 [1996];
- Vasey et al., Clin. Cancer Res., 5:83 [1999];
- Capala et al., Bioconjugate Chem., 7:7 [1996];

- Selman, et al., Photochem. Photobiol., 57:681-85 [1993];
- Brasseur *et al.*, Photochem. Photobiol., 47:705-11 [1988];
- Firey and Rodgers, Photochem. Photobiol., 45:535-38 [1987];
- Sessler *et al.*, Proc. SPIE, 1426:318-29 [1991];
- Chang et al., Proc. SPIE, 1203:281-86 [1990];
- Cincotta et al., SPIE Proc., 1203:202-10 [1990];
- Pandey *et al.*, Photochem. Photobiol., 53:65-72 [1991];
- Botchway *et al.*, Photochem. Photobiol. 67(7):635-40 [1998];
- Liao et al., PNAS 91:2659 [1994];
- Haugland, Handbook of Fluorescent Probes and Research Chemicals, 6th ed. This
  reference is a book and is not being supplied at this time;
- Murphy et al., Neuropharm. 33:1375-85 [1994];
- Bourassa et al., JACS 119:2853-60 [1997];
- De Leo and Ford, JACS 121:1980-81 [1999];
- Chan and Nie, Science 281:2016 [1998];
- Sooklal, Adv. Mater., 10:1083 [1998];
- Balogh et al., Proc. of ACS PMSE 77:118 [1997];
- Balogh and Tomalia, J. Am. Che. Soc., 120:7355 [1998];
- Wiener et al., Mag. Reson. Med. 31:1 [1994];
- Wong et al., Ivest. Rad. 31:26 [1996];
- Farkas et al., SPEI 2678:200 [1997];
- Lester *et al.*, Cell Mol. Biol. 44:29 [1998];
- Shortreed *et al.*, J. Phys. Chem., 101:6318 [1997];
- Talanian et al., J. Biol. Chem., 272: 9677 [1997];
- Abrams et al., Development 117:29 [1993];
- Hockenbery et al., Cell 75:241 [1993];
- Wiener et al., Invest. Radiol., 32:748 [1997];
- Capala et al., Bioconjugate Chem., 7:7 [1996];
- Penault-Llorca *et al.*, Int. J. Cancer 61:170 [1995];
- Press *et al.*, Oncogene 5:953 [1990];
- Pegram et al., Proc. Am. Soc. Clin. Oncol., 14:106 [1995];
- Park et al., Cancer Lett., 118:153 [1997];

- Kirpotin *et al.*, Biochem., 36:66 [1997];
- Kjeldsen et al., Cancer Res. 48:2214-2220 [1988];
- Springer et al., Carbohydr. Res. 178:271-292 [1988];
- Tjandra et al., Br. J. Surg. 75:811-817 [1988];
- Ishida *et al.*, Tumor Biol. 10:12-22 [1989];
- Lan et al., Cancer Res. 45:305-310 [1985];
- Hanisch *et al.*, Carbohydr. Res. 178:29-47 [1988];
- Hinoda et al., (1988) Cancer J. 42:653-658 [1988];
- Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory
   Press, Cold Spring Harbor, NY. This reference is a book and is not being supplied at this time;
- Köhler and Milstein, Nature 256:495-497 [1975];
- Kozbor *et al.* Immunol. Today 4:72 [1983];
- Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985];
- Cote et al., Proc. Natl. Acad. Sci. U.S.A.80:2026-2030 [1983];
- Huse *et al.*, Science 246:1275-1281 [1989];
- Duncan et al., Polymer Preprints 39:180 [1998];
- Sharon and Lis, Science 246:227 [1989];
- Monsigny *et al.*, Biochemie 70:1633 [1988];
- Page and Roy, Bioconjugate Chem., 8:714 [1997];
- Cortese et al., Curr. Opin. Biotechol., 6:73 [1995];
- Goodwin and Meares, Cancer (suppl.) 80:2675 [1997];
- Wilbur et al., Bioconjugate Chem., 9:813 [1998];
- Barth et al., Cancer Investigation 14:534 [1996];
- Duncan and Sat, Ann. Oncol., 9:39 [1998];
- Malik et al., Proc. Int'l. Symp. Control. Rel. Bioact. Mater., 24:107 [1997];
- Wies *et al.*, Nature 333: 426 [1988];
- White *et al.*, Cell 56: 725 [1989];
- Wyrick et al., Infect. Imm. 57: 2378 [1989];
- Adlish *et al.*, Virology 176: 337 [1990];
- Krah, Virology 172: 386 [1989];

- Khatzman *et al.*, Nature 312: 763 [1985];
- Sacerdote et al., J. of Neuroscience Research 18: 102 [1987];
- Ruff et al., FEBS Letters 211: 17 [1987];
- Epstein *et al.*, Nature 318: 663 [1985];
- Lentz et al., Science 215: 182 [1982];
- Carel et al., J. Biol. Chem. 265: 12293 [1990];
- Co et al., Proc. Natl. Acad. Sci. 82: 1494 [1985];
- Marlin *et al.*, Nature 344: 70 [1990];
- Shephey *et al.*, Proc. Natl. Acad. Sci. 85: 7743 [1988];
- Mendelsohn et al., Cell 56: 855 [1989];
- Kaner *et al.*, Science 248: 1410 [1990];
- Tuerk et al., Gene 137(1):33-9 [1993];
- Binkley et al., Nuc. Acids Res. 23(16):3198-205 [1995];
- Jellinek *et al.*, Biochem. 83(34):10450-6 [1994];
- Uppuluri et al., PMSE 80:55 [1999];
- Mosmann, J. Immunol. Meth., 65:55 [1983];
- Kuhlmann *et al.*, Arch. Toxicol., 72:536 [1998];
- International Patent Publication WO 99/02651
- U.S. Patent 5,714,166 to Tomalia *et al*.
- Zhou et al., Journal of Controlled Release 57:249-257 [1999]
- Bielinska et al., Nucleic Acids Research 24:2176-2182 (1996)
- Kukowska-Latallo et al., Proc.Natl. Acad. Sci. USA 93:4897-4902 (1996)
- Bielinska *et al.*, Biochimica et Biophysica Acta 1353:180-190 (1997)
- Wagner, Journal of Controlled Release 53:155-158 (1998)
- Brazeau et al., Pharm. Research 15:680-684 (1998)
- Shchepinov et al., Nucleic Acids Research 25:4447-4454 (1997)
- Haensler et al., Bioconjugate Chem. 4:373-379 (1993)
- Orentas et al., Journal of Virological Methods 77:153-163 (1999)
- Choi *et al.*, Bioconjugate Chem. 10:62-65 (19999)

- Ruponen et al., Biochimica et Biophysica Acta 1415:331-341 (1999)
- Baker *et al.*, Kluwer Academic Publishers, Manufactured in the Netherlands 61-690 (2001)

The below references were cited in the International Search Report of the corresponding PCT application PCT/US01/15204, International Filing Date 11/05/2001.

- International Patent Publication WO 99/61662;
- International Patent Publication WO 97/07398;
- International Patent Publication WO 01/02861;
- EP 0 271 180;
- Pratap Singh, Bioconjugate Chem., 9:54-63 [1998]

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

David A. Casimir Reg. No. 42,395

Dated: August 4, 2005

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 608/218-6900 FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Attorney Docket No.: UM-06609 Serial No.: 09/940,243 INFORMATION SISSIOSURE STATEMENT BY APPLICANT (USES eral Sheets If Necessary) Applicant: James R. Baker, Jr. et al. 8 Filing Date: 08/27/2001 Group Art Unit: (37 CFR § 1 /98(b)) AUG 0 8 2005 8 **U.S. PATENT DOCUMENTS** Cite No. Serial atent Examiner Initials Number Class Subclass Issue Date Applicant / Patentee Filing Date TAM 4.507,466 03/26/85 Tomalia et al. 528 332 01/07/83 12/10/85 528 2 4,558,120; Tomalia et al. 363 12/27/83 3 08/14/84 4,568,737; 02/04/86 528 332 Tomalia et al. 4 4,587,329; 05/06/86 Tomalia et al. 528 363 07/19/85 5 4,631,337; 12/23/86 Tomalia et al. 528 391 07/15/85 6 09/15/87 528 332 02/28/86 4,694,064; Tomalia et al. 7 4,713,975; 12/22/87 Tomalia et al. 73 865.8 05/30/86 8 4,737,550; 04/12/88 525 12/08/86 Tomalia 418 9 02/08/88 4,857,599; 08/15/89 525 259 Tomalia et al. 10 4,871,779; 10/03/89 Killat et al. 521 28 12/23/85 11 08/16/94 Tomalia et al. 1.49 02/13/91 5,338,532; 424 02/07/95 11/08/93 12 5,387,617; Hedstrand et al. 521 79 13 5,393,797; 02/28/95 Hedstrand et al. 521 134 06/13/94 14 5,393,795; 02/28/95 06/13/94 Hedstrand et al. 521 134 15 06/18/96 1.33 04/05/93 5,527,524; Tomalia et al. 424 16 5,560,929; 10/01/96 Hedstrand et al. 424 486 11/12/93 17 06/30/98 Tomalia et al. 525 417 01/20/95 5,773,527; 18 5,631,329; 05/20/97 525 417 03/21/95 Yin et al. 19 5,902,863; 05/11/99 Dvornic et al. 525 431 07/21/97 20 5,795,582; 08/18/98 Wright 424 400 02/07/96 21 5,898,005; 04/27/99 Singh et al. 436 527 04/13/94 5,861,319; 10/28/94 22 01/19/99 Lin et al. 436 527 23 5,661,025; 08/26/97 Szoka et al. 435 172.3 06/07/95 24 4,946,778; 08/07/90 Ladner et al. 435 69.6 01/19/89 25 08/10/99 12/09/96 5,935,114; 604 264 Jang et al. 26 5,908,413; 06/01/99 604 529 10/03/97 Lange et al. 27 5,792,105; 08/11/98 Lin et al. 604 96 09/11/96 28 5,693,014; 12/02/97 Abele et al. 604 96 05/15/95 29 10/07/97 07/23/93 5,674,192; Sahatjian et al. 604 28 30 5,876,445; 03/02/99 Andersen et al. 623 11 11/26/96 31 06/22/99 10/20/95 5,913,894; Schmitt 623 1 32 5,868,719; 02/09/99 265 01/15/97 Tsukernik 604 33 5,851,228; 12/22/98 Pinheiro 623 1 08/22/96 Examiner: Date Considered: EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

(37 CFR § 1.98(b))

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.: UM-06609

Serial No.: 09/940,243

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

Applicant: James R. Baker, Jr. et al.

Filing Date: 08/27/2001

Group Art Unit:

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	34	5,843,089;	12/01/98	Sahatjian <i>et al</i> .	606	108	09/20/96
	35	5,800,519;	09/01/98	Sandock	623	1	11/04/96
	36	5,800,508;	09/01/98	Goicoechea et al.	623	1	06/05/95
	37	5,800,391;	09/01/98	Kontos	604	96	03/15/96
	38	5,354,308;	10/11/94	Simon et al.	606	198	05/01/92
	39	5,755,722;	05/26/98	Barry et al.	606	108	12/22/94
	40	5,733,303	03/31/98	Israel et al.	606	198	05/31/95
	41	5,866,561;	02/02/99	Ungs	514	182	08/21/97
	42	5,857,998;	01/12/99	Вагту	604	96	06/02/97
	43	5,843,003;	withdrawn			,	
	44	5,933,145;	08/03/99	Meek	345	348	04/17/97
	45	5,892,020;	04/06/99	Mezes et al.	536	23.53	06/07/95
	46	5,892,019;	04/06/99	Schlom et al.	536	23.53	09/01/94
	47	5,512,443;	04/30/96	Schlom et al.	435	7.23	07/02/90
	48	5,693,763	12/02/97	Codington et al.	530	387.7	06/06/95
	49	5,545,530;	08/13/96	Satomura et al.	435	6	05/17/95
	50	5,808,005;	09/15/98	Codington et al.	530	395	06/06/95
	51	4,708,930;	11/24/87	Kortright et al.	435	7	02/15/85
	52	4,743,543;	05/10/88	Kortright	435	7	09/09/85
	53	4,921,789;	05/01/90	Salem et al.	435	7	04/20/88
	54	4,921,790;	05/01/90	O'Brien	435	7	04/24/87
	55	5,110,911;	05/05/92	Samuel et al.	530	395	11/02/89
	56	5,855,866	01/05/99	Thorpe et al.	424	1.49	03/02/94
	57	4,963,484;	10/16/90	Kufe	435	69.3	01/29/88
	58	5,053,489;	10/01/91	Kufe	530	350	01/27/89
	59	4,939,240	07/03/90	Chu et al.	530	387	09/11/85
	60	4,918,164;	04/17/90	Hellstrom et al.	530	387	11/04/87
	61	4,914,021;	04/03/90	Toth et al.	435	7	03/04/88
	62	4,892,935;	01/09/90	Yoshida et al.	530	387	07/06/87
	63	5,475,096;	12/12/95	Gold et al.	563	23.1	06/10/91
	64	5,270,163;	12/14/93	Gold et al.	435	6	08/17/92
	65	5,714,166	02/03/98	Tomalia et al.	424	486	03/07/95

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Attorney Docket No.: UM-06609 Serial No.: 09/940,243 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Applicant: James R. Baker, Jr. et al. Filing Date: 08/27/2001 Group Art Unit: (37 CFR § 1.98(b)) FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS Translation Document Number **Publication Date** Country / Patent Office Class Subclass Yes No WO 97/38134 66 **PCT** 67 WO 98/33941; PCT 68 WO 99/07724; **PCT** 69 PCT/US90/02545 PCT WO 99/02651 70 **PCT** OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) 71 Friedman, Cancer 70:1810 [1992] 72 Kerr et al., Cancer 73:2013 [1994]; 73 Cohen and Tohoku, Exp. Med., 168:351 [1992]; 74 Fujiwara et al., J. Natl. Cancer Inst., 86:458 [1994]; 75 Tomalia, Advanced Materials 6:529 [1994]; 76 Tomalia, Angew, Chem. Int. Ed. Engl., 29:138 [1990] 77 Tomalia et al., Chem. Int. Ed. Engl., 29:5305 [1990]; 78 Yin et al., J. Am. Chem. Soc., 120:2678 [1998]; 79 Roberts et al., J. Biomed. Mat. Res., 30:53 [1996] 80 Bourne et al., J. Magn. Reson. Imag., 6:305 [1996]; 81 Singh et al., Clin. Chem., 40:1845 [1994]; 82 Wu et al., Bioorg. Med. Chem. Lett., 4:449 [1994]; 83 Wiener et al., Magn. Reson. Med. 31:1 [1994] 84 Barth et al., Bioconjugate Chem. 5:58 [1994]; 88 Duncan and Malik, Control Rel. Bioact. Mater. 23:105 [1996]; 86 Baker et al., Anal. Chem. 69:990 [1997]; 87 Urdea and Hom, Science 261:534 [1993]; 88 Lanni et al., Proc. Natl. Acad. Sci., 94:9679 [1997]; 89 Tortora et al., Cancer Research 57:5107 [1997]; 90 Zaffaroni et al., Brit. J. Cancer 77:1378 [1998]; 91 Yu et al., Molecular Cell. 2:581 [1998]; 92 Gibb, Gynecologic Oncology 65:13 [1997]; 93 Akutsu et al., Eur. J. Cancer 31A:2341 [1995]; Goodman and Gilman's "Pharmaceutical Basis of Therapeutics" ninth edition, Eds. Hardman et al., 1996. This reference is a book and is not being supplied at this time. 94 Examiner: Date Considered: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. EXAMINER:

FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.: UM-06609

Serial No.: 09/940,243

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

Applicant: James R. Baker, Jr. et al.

(37 CFR § 1.98(b))	(Ose Several Stices in Necessary)	Filing Date: 08/27/2001	Group Art Unit:					
	OTHER DOCUMENTS (Including Author, Title, D	ate, Relevant Pages, Place of Publication)						
95	Pasani et al., Inorg. Chim. Acta 80:99 [1983]							
96 Ottl et al., Bioconjugate Chem., 9:143 [1998];								
97 Abel et al., Eur. J. Cancer 9:4 [1973];								
.98	98 Pillai, V.N.R. Synthesis: 1-26 [1980]; 99 Esfand et al., Pharm. Sci., 2:157 [1996]; 100 Vasey et al., Clin. Cancer Res., 5:83 [1999]; 101 Capala et al., Bioconjugate Chem., 7:7 [1996]							
99								
100								
101								
102 Selman, et al., Photochem. Photobiol., 57:681-85 [1993];								
103	Brasseur et al., Photochem. Photobiol., 47:705-11 [1988];							
104								
105 Sessler et al., Proc. SPIE, 1426:318-29 [1991];  106 Chang et al., Proc. SPIE, 1203:281-86 [1990];								
							107 Cincotta et al., SPIE Proc., 1203:202-10 [1990];	
108								
109								
110 Liao et al., PNAS 91:2659 [1994];  Haugland, Handbook of Fluorescent Probes and Research Chemicals, 6th ed. This reference is a book and is not being supplied at the								
						112		
113								
114								
115								
116	Sooklal, Adv. Mater., 10:1083 [1998]							
117 Balogh <i>et al.</i> , Proc. of ACS PMSE 77:118 [1997];  118 Balogh and Tomalia, J. Am. Che. Soc., 120:7355 [1998];  119 Wiener <i>et al.</i> , Mag. Reson. Med. 31:1 [1994];								
					120	Wong et al., Ivest. Rad. 31:26 [1996];		
					121	Farkas et al., SPE1 2678:200 [1997];		
122	Lester et al., Cell Mol. Biol. 44:29 [1998];							
123 -	Shortreed et al., J. Phys. Chem., 101:6318 [1997];							
124	Talanian et al., J. Biol. Chem., 272: 9677 [1997];							
125	Abrams et al., Development 117:29 [1993];	· · · · · · · · · · · · · · · · · · ·	<del></del>					
126	Hockenbery et al., Cell 75:241 [1993];							
127	Wiener et al., Invest. Radiol., 32:748 [1997];		<del> </del>					
128	Capale et al., Bioconjugate Chem., 7:7 [1996];							
129	Penault-Llorca et al., Int. J. Cancer 61:170 [1995];	· · · · · · · · · · · · · · · · · · ·	. <del></del>					
Examiner:	1	Date Considered:						
	*							

FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Serial No.: 09/940,243 Attorney Docket No.: UM-06609 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Applicant: James R. Baker, Jr. et al. Filing Date: 08/27/2001 Group Art Unit: (37 CFR § 1.98(b)) OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) 130 Press et al., Oncogene 5:953 [1990]; 131 Pegrarn et al., Proc. Am. Soc. Clin. Oncol., 14:106 [1995]; 132 Park et al., Cancer Lett., 118:153 [1997]; 133 Kirpotin et al., Biochem., 36:66 [1997] 134 Kjeldsen et al., Cancer Res. 48:2214-2220 [1988]; 135 Springer et al., Carbohydr. Res. 178:271-292 [1988]; 136 Tjandra et al., Br. J. Surg. 75:811-817 [1988]; 137 Ishida et al., Tumor Biol. 10:12-22 [1989]; 138 Lan et al., Cancer Res. 45:305-310 [1985]; 139 Hanisch et al., Carbohydr. Res. 178:29-47 [1988]; 140 Hinoda et al., (1988) Cancer J. 42:653-658 [1988]; Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. This reference is a book and is not being supplied at this time. 141 142 Köhler and Milstein, Nature 256:495-497 [1975]; 143 Kozbor et al. Immunol. Today 4:72 [1983]; 144 Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985] 145 Cote et al., Proc. Natl. Acad. Sci. U.S.A.80:2026-2030 [1983]; 146 Huse et al., Science 246:1275-1281 [1989]; 147 Duncan et al., Polymer Preprints 39:180 [1998]; 148 Sharon and Lis, Science 246:227 [1989]; 149 Monsigny et al., Biochemie 70:1633 [1988]; 150 Page and Roy, Bioconjugate Chem., 8:714 [1997]; 151 Cortese et al., Curr. Opin. Biotechol., 6:73 [1995]; 152 Goodwin and Meares, Cancer (suppl.) 80:2675 [1997]; 153 Wilbur et al., Bioconjugate Chem., 9:813 [1998]; 154 Barth et al., Cancer Investigation 14:534 [1996]; 155 Duncan and Sat, Ann. Oncol., 9:39 [1998]; 156 Malik et al., Proc. Int'l. Symp. Control. Rel. Bioact. Mater., 24:107 [1997] 157 Wies et al., Nature 333: 426 [1988]; 158 White et al., Cell 56: 725 [1989]; 159 Wyrick et al., Infect. Imm. 57: 2378 [1989]; 160 Adlish et al., Virology 176: 337 [1990]; 161 Krah, Virology 172: 386 [1989] 162 Khatzman et al., Nature 312: 763 [1985]; 163 Sacerdote et al., J. of Neuroscience Research 18: 102 [1987]; Examiner: Date Considered: **EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449 U.S. Department of Commerce Attorney Docket No.: UM-06609 Serial No.: 09/940,243 (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Applicant: James R. Baker, Jr. et al. (37 CFR § 1.98(b)) Filing Date: 08/27/2001 Group Art Unit: OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) 164 Ruff et al., FEBS Letters 211: 17 [1987]; 165 Epstein et al., Nature 318: 663 [1985]; 166 Lentz et al., Science 215: 182 [1982]; 167 Carel et al., J. Biol. Chem. 265: 12293 [1990]; 168 Co et al., Proc. Natl. Acad. Sci. 82: 1494 [1985]; 169 Marlin et al., Nature 344: 70 [1990]; 170 Shephey et al., Proc. Natl. Acad. Sci. 85: 7743 [1988] 171 Mendelsohn et al., Cell 56: 855 [1989]; 172 Kaner et al., Science 248: 1410 [1990]; 173 Tuerk et al., Gene 137(1):33-9 [1993]; 174 Binkley et al., Nuc. Acids Res. 23(16):3198-205 [1995]; 175 Jellinek et al., Biochem. 83(34):10450-6 [1994]; 176 Uppuluri et al., PMSE 80:55 [1999]; 177 Mosmann, J. Immunol. Meth., 65:55 [1983] 178 Kuhlmann et al., Arch. Toxicol., 72:536 [1998]; 179 Bielinska et al., Nucleic Acids Research 24:2176-2182 (1996) 180 Kukowska-Latallo et al., Proc.Natl. Acad. Sci. USA 93:4897-4902 (1996) 181 Bielinska et al., Biochimica et Biophysica Acta 1353:180-190 (1997) 182 Wagner, Journal of Controlled Release 53:155-158 (1998) 183 Brazeau et al., Pharm. Research 15:680-684 (1998) 184 Shchepinov et al., Nucleic Acids Research 25:4447-4454 (1997) 185 Haensler et al., Bioconjugate Chem. 4:373-379 (1993) 186 Orentas et al., Journal of Virological Methods 77:153-163 (1999) 187 Choi et al., Bioconjugate Chem. 10:62-65 (19999) 188 Ruponen et al., Biochimica et Biophysica Acta 1415:331-341 (1999)

Examiner: EXAMINER: 189

190

191

Date Considered:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Baker et al., Kluwer Academic Publishers, Manufactured in the Netherlands 61-690 (2001)

Pratap Singh, Bioconnugate Chem., 9:54-63 [1998]

Zhou et al., Journal of Controlled Release 57:249-257 [1999]

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet | 7

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete il Known				
Application Number	10/402,287 09940243			
Filing Date	08/27/01			
First Named Inventor	Baker			
Art Unit	1635			
Examiner Name	Ashen			
Attorney Docket Number	UM-06609			

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (# known)</sup> US-			- I I I I I I I I I I I I I I I I I I I
		08-	1		
		US-			
-		US-	1		
		US-			
		US-			
	<del></del>	US-		-	
		US-			
		US-	<del> </del> -		
		US-		7.0 <b>a</b>	
		US-	_		-
		US-			
		US-	-		
	l .	US-	<del> </del>		

		FOREIG	N PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3 "</sup> Number <sup>4 "</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
	192	WO 99/61662	02/12/99	PCT		
	193	WO 97/07398	27/02/97	PCT		
	194	WO 01/02861	11/01/01	PCT		
	195	EP 0 271 180	15/06/1988	EP		
				İ		

Examiner		Date	
Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.